

## Media release

Zug, 27 January 2017

### **Two IPOs from the HBM Healthcare Investments portfolio increase net asset value per HBM-share by CHF 2.30**

Two members of the HBM Healthcare Investments portfolio of private companies went public yesterday: Swiss ObsEva, and California-based Anaptys Biosciences.

ObsEva (Nasdaq: OBSV) issued 6.45 million new shares at a price of USD 15.00 per share, thereby raising USD 96.75 million. The share price declined by 22.3% to USD 11.65 on its first day of trading.

HBM Healthcare Investments first invested the equivalent of USD 9.9 million in ObsEva in November 2015, when it acquired 1.85 million shares at a price of USD 5.35. Following the IPO it holds 2.4 million shares at a total value of USD 28.1 million, which corresponds to an 8% stake in the company.

By going public, Anaptys Biosciences (Nasdaq: ANAB) raised USD 75 million in capital by issuing 5 million shares at a price of USD 15.00 per share. Anaptys shares closed their first day of trading at USD 17.00 (+13.3%).

HBM Healthcare Investments initially took a stake in Anaptys in July 2015, acquiring 0.94 million shares at a price of USD 7.42 each, i.e. a total investment of USD 7 million. HBM Healthcare Investments holds around 1 million shares at a total value of USD 17 million after the IPO, which corresponds to an ownership of about 5% in the company.

The two IPOs combined raise the net asset value per HBM-share by CHF 2.30 (+1.6%).

For further information, please contact Dr. Andreas Wicki, Tel. +41 41 710 75 77, [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

### Information on HBM Healthcare Investments Ltd.

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

### HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)